Clinical study on microscopic syndrome differentiation and traditional Chinese medicine treatment for liver stomach disharmony in chronic gastritis

Table 1 Baseline characteristics of the two groups

	Treatment group (n = 64)	Control group (n = 64)	P value
Age (yr)	46.3 ± 11.2	45.6 ± 10.8	0.68
Sex (male/female)	32/32	33/31	0.82
Body mass index (kg/m2)	23.5 ± 3.2	23.7 ± 3.4	0.76
Duration of disease (months)	27.4 ± 15.6	26.8 ± 16.2	0.84
Helicobacter pylori status (positive/negative)	38/26	37/27	0.88
NDI score	42.7 ± 8.9	43.1 ± 9.2	0.79
MLS score	6.4 ± 2.1	6.5 ± 2.2	0.87
USS score	9.3 ± 3.4	9.5 ± 3.6	0.81
Microcosmic syndrome score	12.6 ± 4.8	12.8 ± 4.9	0.83

NDI: Nepean Dyspepsia Index; MLS: Modified Lanza score; USS: Updated Sydney system.

Table 2 Improvement rate of dyspeptic symptoms of the two groups at different time points

Time point	Treatment group improvement rate of dyspeptic symptoms (%)	Control group improvement rate of dyspeptic symptoms (%)	P value
4 wk	48.7 ± 15.3	24.6 ± 12.4	< 0.01
8 wk	67.4 ± 18.2	35.7 ± 16.7	< 0.01
12 wk	93.8 ± 12.6	65.6 ± 19.4	< 0.01

Table 3 Improvement rate of microcosmic syndrome scores of the two groups at different time points

Time point	Treatment group improvement rate of microcosmic syndrome scores (%)	Control group improvement rate of microcosmic syndrome scores (%)	P value
4 wk	28.6 ± 14.5	25.4 ± 13.6	0.42
8 wk	46.8 ± 18.7	40.6 ± 17.9	0.26
12 wk	64.3 ± 21.3	58.9 ± 22.4	0.37

Table 4 Incidence and type of adverse events in the two groups, n (%)

Adverse events	Treatment group (n = 64)	Control group (n = 64)	P value
Total adverse events	6 (9.4)	8 (12.5)	0.57
Diarrhea	2 (3.1)	3 (4.7)	0.89
Nausea	1 (1.6)	2 (3.1)	0.85
Headache	2 (3.1)	1 (1.6)	0.79
Rash	1 (1.6)	2 (3.1)	0.81